Pharmaceuticals
KANEKA UBIQUINOL™ AWARDED PRESTIGIOUS COMPLEMENTARY MEDICINES AUSTRALIA RAW MATERIAL SUPPLIER OF THE YEAR AWARD 2024
SYDNEY, Dec. 6, 2024 /PRNewswire/ -- Kaneka Ubiquinol™ has been awarded the
covetedRaw Material Supplier of the Year Award 2024 at the Complementary
Medicines Australia (CMA) Awards, held inSydney this evening.
2024-12-06 06:10
3028
AtomVie Global Radiopharma Appoints Dr. Pratibhash Chattopadhyay as Chief Business Officer to Accelerate Growth and Strengthen Leadership
HAMILTON, ON, Dec. 5, 2024 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, is pleased to announce the appointment of Dr. Pratibhash (Bosh) Chattopadhyay as Chief Business Officer. Dr. Chattopadhyay brings over 25 years of commercial and technical ...
2024-12-05 22:00
1561
Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing
EAST RUTHERFORD, N.J., Dec. 5, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly...
2024-12-05 19:00
2519
NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
MILAN, Dec. 5, 2024 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered inItaly, presents positive results from Phase II MIRAKLE study, a multicentre, randomized, blinded-assessor, phase II non-inferiority study evaluatingthe efficacy and tolerability of NTC014 ...
2024-12-05 19:00
2525
CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial
MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). Key...
2024-12-05 11:59
2525
LBB Specialties and Clariant Partner to Distribute High-Quality Pharmaceutical Grade PEGs for Ophthalmic Applications
NORWALK, Conn., Dec. 5, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, announced a strategic partnership with Clariant, a global leader in specialty chemical manufacturing. Through this collaboration, LBB Specialties will ...
2024-12-05 04:02
1935
China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke
NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved for marketing by the National Medical Products Admini...
2024-12-04 18:10
2728
Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced or metastat...
2024-12-04 13:09
2156
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved mapping and dual energy ablation catheter
AUSTIN, Texas, Dec. 4, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to use an all-in-one high-density mapping and dual energy ablation catheter for the treatment of persistent atria...
2024-12-04 10:07
2545
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
* Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission. * In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and ...
2024-12-04 09:10
2956
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...
2024-12-04 08:00
3492
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
* VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery * Statistically and clinically meaningful reductions in inflammation and ...
2024-12-04 00:00
2449
Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter
– Provides interventionalists with optimal product choices for more complex radial-to-peripheral procedures– SOMERSET, N.J., Dec. 3, 2024 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, is pleased to announce the launch and commercial availability of its R2...
2024-12-03 21:00
1724
Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts
INCHEON, South Korea, Dec. 3, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day to share insights on sustainable management and encourage ESGactions among suppliers. Second of i...
2024-12-03 20:00
2016
Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), will be included in the Hang Seng Hong Ko...
2024-12-03 18:47
1975
AC Health makes critical HIV care more accessible to Filipinos with USAID support
MANILA, Philippines, Dec. 3, 2024 /PRNewswire/ -- Ayala Healthcare Holdings, Inc. (AC Health), in partnership with the U.S. Agency for International Development (USAID), is leading the private sector's efforts to fight the HIV epidemic inthe Philippines by improving access to stigma-free care and...
2024-12-03 16:11
5721
Pfizer Receives Authorization from Health Authority for Its 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
* In Hong Kong, the 20-valent Pneumococcal Conjugate Vaccine (PCV20) that offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine – helping to fight against 20 serotypesleading to most of the invasive pneumococcal diseases and pneumonia[i],[ii] – is now approved fo...
2024-12-03 15:08
2468
Fosun's Rural Doctors Program Recognized in UNGC's "20 Cases of Private Sector's Sustainable Development in China for 20 Years" Report
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- This year marks the 20th anniversary of the United Nations Global Compact ("UNGC")'s introduction of Environmental, Social, and Governance (ESG) concept and principles. On29 November 2024, the UNGC held a launch event for the "20 Cases of Private Sector's S...
2024-12-03 11:47
2671
European Wellness Biomedical Group, Headed by Prof. Mike Chan, Releases New Study on Bioregenerative Blueprint for Athletic Longevity
KOTA KINABALU, Malaysia, Dec. 2, 2024 /PRNewswire/ -- European Wellness Biomedical Group (EWBG), a global leader in regenerative medicine, has unveiled a groundbreaking study led by renowned expert Prof.Mike Chan on the physiological challenges aging athletes face. The analysis explores how age ...
2024-12-02 16:30
3762
MGI Tech announces partnership with Universidad de San Martín de Porres to strengthen human genetics research
* The implementation of MGI Tech's next-generation genomic sequencing (NGS) technologies will strengthen scientific research in the country, enabling the identification of key genetic variations, contributing to disease prevention, and personalizing medical treatments. * A team of specialists...
2024-12-02 11:16
1795
Week's Top Stories
Most Reposted
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 318 media titles]
2026-02-02 10:00
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 284 media titles]
2026-02-01 19:35